In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown remarkable weight loss efficacy in global clinical trials. In China, the SURMOUNT-CN trial marked the first phase 3 study evaluating ...